- Home
- AR vs UTHR Comparison
AR vs UTHR Comparison
Compare AR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AR
- UTHR
- Stock Information
- Founded
- AR 2002
- UTHR 1996
- Country
- AR United States
- UTHR United States
- Employees
- AR N/A
- UTHR N/A
- Industry
- AR Oil & Gas Production
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- AR Energy
- UTHR Health Care
- Exchange
- AR Nasdaq
- UTHR Nasdaq
- Market Cap
- AR 12.7B
- UTHR 14.4B
- IPO Year
- AR 2013
- UTHR 1999
- Fundamental
- Price
- AR $34.42
- UTHR $284.73
- Analyst Decision
- AR Buy
- UTHR Buy
- Analyst Count
- AR 18
- UTHR 12
- Target Price
- AR $40.94
- UTHR $388.25
- AVG Volume (30 Days)
- AR 6.1M
- UTHR 499.4K
- Earning Date
- AR 04-30-2025
- UTHR 04-30-2025
- Dividend Yield
- AR N/A
- UTHR N/A
- EPS Growth
- AR N/A
- UTHR 24.38
- EPS
- AR 0.18
- UTHR 24.64
- Revenue
- AR $4,297,764,000.00
- UTHR $2,877,400,000.00
- Revenue This Year
- AR $36.14
- UTHR $11.52
- Revenue Next Year
- AR $3.16
- UTHR $6.08
- P/E Ratio
- AR $187.85
- UTHR $11.56
- Revenue Growth
- AR N/A
- UTHR 23.63
- 52 Week Low
- AR $24.53
- UTHR $233.28
- 52 Week High
- AR $42.63
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- AR 44.02
- UTHR 37.49
- Support Level
- AR $32.70
- UTHR $266.98
- Resistance Level
- AR $34.51
- UTHR $288.54
- Average True Range (ATR)
- AR 2.55
- UTHR 14.43
- MACD
- AR -0.36
- UTHR -0.15
- Stochastic Oscillator
- AR 36.35
- UTHR 38.23
About AR Antero Resources Corporation
Antero Resources, based in Denver, engages in the exploration for and production of natural gas and natural gas liquids in the United States and Canada. At the end of 2024, the company reported proven reserves of 17.9 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,424 million cubic feet of equivalent a day in 2024 at a ratio of 35% liquids and 65% natural gas.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.